© 2020 MJH Life Sciences and OncLive. All rights reserved.
February 28, 2013
Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, describes a study that discovered JAK2 alterations in patients with treatment-refractory triple-negative breast cancer.
December 08, 2012
Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.